Download New Combination Approaches To Enhance Rituximab Based Lymphoma Therapies Book PDF

Download full New Combination Approaches To Enhance Rituximab Based Lymphoma Therapies books PDF, EPUB, Tuebl, Textbook, Mobi or read online New Combination Approaches To Enhance Rituximab Based Lymphoma Therapies anytime and anywhere on any device. Get free access to the library by create an account, fast download and ads free. We cannot guarantee that every book is in the library.

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies

New Combination Approaches to Enhance Rituximab-Based Lymphoma Therapies
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2020-07-15
  • Total pages :250
  • ISBN : 0128164077
GET BOOK HERE

Summary : New Combination Approaches to Enhance Rituximab-based Lymphoma Therapies provides general updated information on the resistance of various human lymphoma/leukemia subtypes to anti-CD20 therapeutic antibodies. It discusses also the description of various targeted sensitizing agents that can reverse innate or acquired resistance when used in combination with various FDA-approved anti-CD20 antibodies. There have been a lot of reports in which the treatment with anti-CD20 antibodies for various lymphomas/leukemias has resulted in significant clinical responses; however, there have been also subsets of cancer patients who did not respond initially and several of the responding patients developed resistance to subsequent treatments with the same or different regimens. Therefore, the use of various immunosensitizing agents targeting resistant factors to reverse resistance has been considered and this book discusses each of them in depth, such as Bortexomib, Immunomodulation Agents, Obinutuzumab, Tumor Suppressors, and HDAC Inhibitors. This book is a valuable source for cancer researchers, oncologists, pharmacologists and different members of biomedical field interested in fighting cancer resistance to anti-CD20 antibodies. Provides a general overview of various sensitizing agents that can work effectively when used in combination with anti-CD20 antibodies to reverse resistance Offers potential underlying mechanisms by which the cancer cells are either inherently resistant or become unresponsive to further antibody treatments Discusses how to develop new targeted agents to underlie resistance in order to expand research on this field

Journal of the National Cancer Institute

Journal of the National Cancer Institute
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2002
  • Total pages :229
  • ISBN : UCR:31210015965740
GET BOOK HERE

Summary :

Yonsei Medical Journal

Yonsei Medical Journal
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :229
  • ISBN : MINN:31951P01070862B
GET BOOK HERE

Summary :

Perry's The Chemotherapy Source Book

Perry's The Chemotherapy Source Book
  • Author : Michael C. Perry,Donald C. Doll,Carl E. Freter
  • Publisher :Unknown
  • Release Date :2012-07-30
  • Total pages :848
  • ISBN : 9781469803432
GET BOOK HERE

Summary : Perry’s The Chemotherapy Source Book, now in its fifth edition, provides information on the choice of chemotherapeutic agents, the use of combination chemotherapy, and the toxicity of individual drugs. Organized by site, this is the only book of its kind to focus strictly on the clinical practice of chemotherapy, and is meant to serve as a “one-stop shop” for information on choice of chemotherapeutic agents, treatment outlines, grading of side effects, and dose modification.

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy

Combinatorial Approaches to Enhance Anti-Tumor Immunity: Focus on Immune Checkpoint Blockade Therapy
  • Author : Patrik Andersson,Christian Ostheimer
  • Publisher :Unknown
  • Release Date :2019-12-27
  • Total pages :229
  • ISBN : 9782889631612
GET BOOK HERE

Summary : The immune system harbors great potential for controlling and eliminating tumors. Recent developments in the field of immuno-oncology has led to unprecedented clinical benefits for a broad spectrum of solid tumors. However, immunotherapy (IT) approaches currently have several limitations including (i) low response rate; (ii) development of resistance and (iii) causing severe immune-related adverse effects (IrAEs), which underline the importance of adequate patient selection. Importantly, IT holds promising synergistic potential when combined with standard-of-care chemotherapy, radiotherapy (RT) and anti-angiogenic therapy (AAT) as part of multi-modal oncologic treatment regimes. Published data suggest that there are potential synergy between RT and AAT, which ultimately could help potentiate the response to IT. However, the complex interactions between RT and IT and/or AAT remain poorly understood. Many research questions including optimal timing, scheduling and dosing, as well as patient selection and side effects of combined therapy approaches, remain to be addressed. This Research Topic aims to give a comprehensive overview of the current field with particular emphasis on the future outlook of RT and AAT as complementary approaches to improve IT in solid tumors.

Cancer Research

Cancer Research
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2009-12
  • Total pages :229
  • ISBN : CORNELL:31924108306014
GET BOOK HERE

Summary :

Immunotherapy and The Regulatory Immune System in Blood Cancers: From Mechanisms to Clinical Applications

Immunotherapy and The Regulatory Immune System in Blood Cancers: From Mechanisms to Clinical Applications
  • Author : Ken H. Young,Andrés José María Ferreri,Alexandar Tzankov,Naval Daver
  • Publisher :Unknown
  • Release Date :2019-08-16
  • Total pages :229
  • ISBN : 9782889459810
GET BOOK HERE

Summary :

High Dose Chemotherapy

High Dose Chemotherapy
  • Author : Paul C. Lorigan,Elisabeth Vandenberghe
  • Publisher :Unknown
  • Release Date :2002-04-11
  • Total pages :336
  • ISBN : 9058232328
GET BOOK HERE

Summary : This text presents an overview of the basic science and principles of high dose chemotherapy, current state-of-the-art techniques and future developments such as gene therapy. The main section of the book is disease-based, setting the scientific principles within a clinical context and reviewing the application of high dose therapy in specific diseases. Additional sections discuss supportive care and long-term complications. High Dose Chemotherapy is directed at hematologists, clinical and medical oncologists in training or with an interest, rather than direct involvement, in the field.

Treatment of Cancer

Treatment of Cancer
  • Author : Pat Price,Karol Sikora
  • Publisher :Unknown
  • Release Date :2020-11-24
  • Total pages :614
  • ISBN : 9780429651649
GET BOOK HERE

Summary : Treatment of Cancer is a multi-author work and comprehensive guide on modern cancer treatment that aims to give clinician and student alike the framework for an integrated approach to patient care, including radiotherapy, chemotherapy, and surgery. Much information is presented in tables and charts for easy assimilation, and clear algorithms for patient pathways are included to make decisions straightforward while allowing for sound clinical judgement.

Non-Myeloablative Allogeneic Transplantation

Non-Myeloablative Allogeneic Transplantation
  • Author : Asad Bashey,Edward D. Ball
  • Publisher :Unknown
  • Release Date :2002-02-28
  • Total pages :216
  • ISBN : 0792376463
GET BOOK HERE

Summary : Non-myeloablative allogeneic stem cell transplantation (also known as mini-transplantation or reduced-intensity conditioning transplantation) is a major advance in the field of hematopoietic transplantation within the last 5 years. This approach uses non-cytotoxic or reduced-intensity cytotoxic therapy to prepare patients for allografting of hematopoietic stem cells and lymphocytes. It has the potential to deliver the potent anti-tumor immunotherapy and bone marrow replacement capacity of allogeneic stem cell transplantation to patients with reduced treatment-related morbidity and mortality. It may also enable allogeneic transplantation in patients who would be considered ineligible for conventional transplants because of co-morbidity or advanced age. However, this approach may necessitate more careful monitoring of post-transplant chimerism and malignant disease-status than is usual with conventional allografting. There is also controversy regarding the best preparative regimen and graft-versus-host disease prophylaxis to use.

Reversal of Drug Resistance in Non-Hodgkin's Lymphoma by Immunotherapy

Reversal of Drug Resistance in Non-Hodgkin's Lymphoma by Immunotherapy
  • Author : Steve Anthony Alas
  • Publisher :Unknown
  • Release Date :2000
  • Total pages :344
  • ISBN : UCLA:L0081786006
GET BOOK HERE

Summary :

Cutaneous T-Cell Lymphoma

Cutaneous T-Cell Lymphoma
  • Author : Herschel S. Zackheim
  • Publisher :Unknown
  • Release Date :2019-10-02
  • Total pages :152
  • ISBN : 0367393670
GET BOOK HERE

Summary : Cutaneous T-cell lymphoma (CTCL) is a general term for many lymphomas of the skin including mycosis Fungoides and Sezary syndrome. This book presents the state of the art in CTCL epidemiology, clinical features, pathology, immunochemistry, diagnostic molecular techniques, staging and prognosis, and treatment. Edited by one of the leading experts in the disease, Cutaneous T-Cell Lymphoma: Mycosis Fungoides and Sezary Syndrome provides comprehensive coverage of the disease and presents techniques for diagnosis and state-of-the-art treatment modalities, such as ultraviolet light, steroids, and topical chemotherapeutics.

Dissertation Abstracts International

Dissertation Abstracts International
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2008
  • Total pages :229
  • ISBN : STANFORD:36105131549656
GET BOOK HERE

Summary :

The Journal of Immunology

The Journal of Immunology
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :229
  • ISBN : UIUC:30112083160074
GET BOOK HERE

Summary :

Novel Therapeutics for Rare Lymphomas

Novel Therapeutics for Rare Lymphomas
  • Author : Christopher Dittus
  • Publisher :Unknown
  • Release Date :2019-10-23
  • Total pages :253
  • ISBN : 9783030256104
GET BOOK HERE

Summary : This comprehensive volume reviews the clinical presentation, diagnosis, and treatment approach to rare lymphomas. There is particular emphasis placed on new diagnostic approaches, novel chemotherapy combinations, and treatment modalities with novel therapeutics. It highlights research advances in a group of diseases that are often overlooked, and serves as a single repository of information on the most recent advances in targeted small molecule inhibitors, monoclonal antibodies, immunotherapy, and CAR-T therapy as they pertain to rare types of lymphoma. Written for practicing oncologists, hematologists, fellows, and residents, Novel Therapeutics for Rare Lymphomas covers rare subtypes of lymphoma, including indolent and aggressive T-cell lymphomas and B-cell lymphomas.

Annual Meeting Proceedings

Annual Meeting Proceedings
  • Author : American Society of Clinical Oncology. Meeting
  • Publisher :Unknown
  • Release Date :2007
  • Total pages :229
  • ISBN : CHI:77004183
GET BOOK HERE

Summary :

Nursing Times, Nursing Mirror

Nursing Times, Nursing Mirror
  • Author : Anonim
  • Publisher :Unknown
  • Release Date :2004
  • Total pages :229
  • ISBN : UCLA:L0090658329
GET BOOK HERE

Summary :

Immunotherapy of Cancer

Immunotherapy of Cancer
  • Author : Mary L. Disis
  • Publisher :Unknown
  • Release Date :2007-10-28
  • Total pages :516
  • ISBN : 9781597450119
GET BOOK HERE

Summary : Expert bench and clinical scientists join forces to concurrently review both the state-of-the-art in tumor immunology and its clinical translation into promising practical treatments. The authors explain in each chapter the scientific basis behind such therapeutic agents as monoclonal antibodies, cytokines, vaccines, and T-cells, and illustrate their clinical manipulation to combat cancer. Additional chapters address statistical analysis-both of clinical trials and assay evaluations-methods for the discovery of antigens, adoptive T cell therapy, and adaptive and innate immunity. The challenges in clinical trial design, the need for biomarkers of response-such as novel imaging techniques and immunologic monitoring-and the new advances and directions in cancer immunotherapy are also fully examined.

Annual Report

Annual Report
  • Author : Ohio State University. Comprehensive Cancer Center. Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
  • Publisher :Unknown
  • Release Date :2000
  • Total pages :229
  • ISBN : OSU:32436010797361
GET BOOK HERE

Summary :

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues
  • Author : E. Campo,N. L. Harris,S. A. Pileri,E. S. Jaffe,H. Stein,J. Thiele
  • Publisher :Unknown
  • Release Date :2017-09-18
  • Total pages :586
  • ISBN : 928324494X
GET BOOK HERE

Summary : WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues is a Revised Fourth Edition of the WHO series on histological and genetic typing of human tumours. This authoritative, concise reference provides an international standard for oncologists and pathologists and will serve as an indispensable guide for use in the design of studies monitoring response to therapy and clinical outcome. Diagnostic criteria, pathological features, and associated genetic alterations are described in a strictly disease-oriented manner. Sections on all recognized neoplasms and their variants further include new ICD-O codes, epidemiology, clinical features, macroscopy, prognosis, and predictive factors. This classification, prepared by 132 authors from 23 countries, contains about 1300 color images and tables and more than 4500 references.

Lymphoma

Lymphoma
  • Author : Anas Younes,Bertrand Coiffier
  • Publisher :Unknown
  • Release Date :2013-05-17
  • Total pages :411
  • ISBN : 9781627034081
GET BOOK HERE

Summary : Recently, understanding the molecular pathogenesis of malignant lymphomas has led to improvement in the diagnostic precision and to the identification of a variety of molecular therapeutic targets. In addition, new drugs have been approved in the US and Europe, resulting in changes in the standard of care of several types of lymphoid malignancies. Comprehensive in scope and developed by a team of internationally renowned authors, Lymphoma: Diagnosis and Treatment provides a timely update on the most important advances in the biology, diagnosis, and therapy of lymphomas. As part of the Current Clinical Oncology series, Lymphoma: Diagnosis and Treatment will be of value to medical oncologists, hematologists, radiation oncologists, and all physicians involved in the care of patients with lymphoid malignancies.